KRTX Stock Recent News

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock has pulled back and is at a good buy level ahead of the upcoming NDA decision (end of this year) and potential FDA approval for KarXT in 2024. KarXT has the potential to become a new standard of care for treating schizophrenia (a large target market), with several advantages over current treatments.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced it will be presenting new secondary efficacy, safety and tolerability, and pooled cognition data from its EMERGENT clinical program evaluating KarXT (xanomeline-trospium) in schizophrenia. The data will be presented at the upcoming 36th European College of N.

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference Date: Wednesday, September 6, 2023 Time: 3:45 p.m. ET Citi's 18th Annual BioPharma Conference Date: Thursday, September 7, 2023 Time: 10:30.

Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023. If FDA approval of KarXT is given for the treatment of patients with schizophrenia then commercial launch of the drug is expected in the second half of 2024. The global schizophrenia drug market is projected to reach $9.48 billion by 2026.

Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizophrenia and Alzheimer's-related psychosis. Karuna Therapeutics faced a net loss of $103.2M in Q2 2023, largely due to increased expenses in research and development, but finished the quarter with $1.4B in cash and equivalents. KarXT shows promising potential in treating schizophrenia and Alzheimer's-related psychosis, with upcoming clinical trial results and a projected NDA submission in 2023.

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Director of Investor Relations William Meury - President and Chief Executive Officer Troy Ignelzi - Chief Financial Officer Andrew Miller - Founder and Chief Operating Officer Conference Call Participants Paul Matteis - Stifel David Amsellem - Piper Sandler Myles Minter - William Blair Jason Butler - JMP Securities Guofang Li - Leerink Partners Jay Olson - Oppenheimer Yatin Suneja - Guggenheim Partners Laura Chico - Wedbush Securities Ram Selvaraju - H.C. Wainwright Jeff Hung - Morgan Stanley Operator Welcome to the Karuna Therapeutics Second Quarter 2023 Financial Results Conference Call.

Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, August 3, 2023 at 8:00 a.m. ET to review second quarter 2023 financial results and provide a general business update. A live webcast of the presentation will be available on the Investor Re.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, at 2:40 p.m. PT (5:40 p.m. ET). A live webcast of the presentation will be available on the Investor Relations page of Karuna's website at.